Nurexone Biologic Stock Debt To Equity
| NRX Stock | 0.71 0.01 1.43% |
NurExone Biologic fundamentals help investors to digest information that contributes to NurExone Biologic's financial success or failures. It also enables traders to predict the movement of NurExone Stock. The fundamental analysis module provides a way to measure NurExone Biologic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NurExone Biologic stock.
NurExone |
NurExone Biologic Company Debt To Equity Analysis
NurExone Biologic's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
NurExone Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, NurExone Biologic has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The debt to equity for all Canada stocks is 100.0% higher than that of the company.
NurExone Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NurExone Biologic's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NurExone Biologic could also be used in its relative valuation, which is a method of valuing NurExone Biologic by comparing valuation metrics of similar companies.NurExone Biologic is currently under evaluation in debt to equity category among its peers.
NurExone Fundamentals
| Return On Equity | -2.54 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 46.99 M | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 4.75 % | ||||
| Number Of Shares Shorted | 32.31 K | ||||
| Price To Book | 13.94 X | ||||
| EBITDA | (4.09 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 1.98 M | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (2.94 M) | ||||
| Short Ratio | 0.58 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Target Price | 4.03 | ||||
| Beta | -0.091 | ||||
| Market Capitalization | 50.3 M | ||||
| Total Asset | 2.17 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | 74 K | ||||
| Net Asset | 2.17 M |
About NurExone Biologic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NurExone Biologic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NurExone Biologic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NurExone Biologic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.